Not Signed In - [ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Growth Hormones |
|
|
Clinical Trial: Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
This study is currently recruiting patients.
|
Purpose
This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Graft Versus Host Disease | Drug: recombinant human keratinocyte growth factor | Phase I Phase II |
MedlinePlus related topics: Immune System and Disorders
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Historical Control, Safety/Efficacy Study
Official Title: Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
Further Study Details:
Expected Total Enrollment: 50
Study start: September 2002; Expected completion: September 2005
Eligibility
Ages Eligible for Study: 3 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor
Location and Contact Information
Christopher Reynolds, MD 734-936-8785 chreynol@med.umich.edu
Michigan
University of Michigan Cancer Center, Ann Arbor, Michigan, 48109, United States; Recruiting
Christopher Reynolds, MD 734-936-8785 chreynol@med.umich.edu
James Ferrara, MD 734-615-1340 Ferrara@umich.edu
James Ferrara, MD, Sub-Investigator
Christopher Reynolds, MD, Principal Investigator
James Ferrara, MD 734-615-1340 Ferrara@umich.edu
James Ferrara, MD, Sub-Investigator
Christopher Reynolds, MD, Principal Investigator
More Information
Study ID Numbers: 2146
Record last reviewed: June 2001
Last Updated: October 13, 2004
Record first received: March 25, 2003
ClinicalTrials.gov Identifier: NCT00056875
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: June 2001
Last Updated: October 13, 2004
Record first received: March 25, 2003
ClinicalTrials.gov Identifier: NCT00056875
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Growth Hormones (National Women's Health Information Center)
email this page
print this page
bookmark this page
feedback on this page
